Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia.
about
Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndromeStructural and functional properties of platelet-derived growth factor and stem cell factor receptorsMolecular mechanism for Rabex-5 GEF activation by Rabaptin-5Genes influencing spinal bone mineral density in inbred F344, LEW, COP, and DA ratsAutomated selection of regions of interest for intensity-based FRET analysis of transferrin endocytic trafficking in normal vs. cancer cellsTargeting the PDGF signaling pathway in tumor treatmentDissecting the molecular mechanism of chronic myelogenous leukemia using murine models.Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias.Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies.Defective downregulation of receptor tyrosine kinases in cancerMolecular classification and pathogenesis of eosinophilic disorders: 2005 update.Myeloproliferative disorders: the centrosome connection.Chronic myeloproliferative disorders: a tyrosine kinase tale.Eosinophilia: secondary, clonal and idiopathic.Can molecular profiling of cytogenetic subgroups draw a roadmap for individualizing therapy in myelodysplastic syndromes?Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.Rabaptin-5 and Rabex-5 are neoplastic tumour suppressor genes that interact to modulate Rab5 dynamics in Drosophila melanogaster.Molecular diagnosis of myeloproliferative neoplasms.Autocrine PDGF stimulation in malignancies.Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.PDGFRᵝ-Rearranged Myeloid Neoplasm with Marked Eosinophilia in a 37-Year-Old Man; And a Literature Review.Traffic jams II: an update of diseases of intracellular transport.Inhibiting the platelet derived growth factor receptor increases signs of retinoic acid syndrome in myeloid differentiated HL-60 cells.PDGFRB-rearranged T-lymphoblastic leukemia/lymphoma occurring with myeloid neoplasms: the missing link supporting a stem cell origin.Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma.KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32).Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.Involvement of platelet-derived growth factor ligands and receptors in tumorigenesis.Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms.The investigation of mutation and single nucleotide polymorphism of receptor tyrosine kinases and downstream scaffold molecules in acute myeloid leukemia.
P2860
Q24670121-3A435ECC-5810-493C-9921-328A149490B3Q26829546-F7F4036C-1458-4FC0-AA89-FC0A3C1D6C25Q27684443-F8BB6FDA-AFD8-449D-93BE-FEA21195B090Q28570822-A7354067-6264-4964-A990-C9292E1251AFQ30407485-9C78F4B1-A16B-4F27-8B1D-CD5D30FF955DQ34393461-BBEC7175-A9D9-42F5-B60F-E8CCC7119B22Q34980358-3296330E-EA1C-4DE5-BD33-D3D6983D0374Q35782893-2C6E619A-F6E2-4812-AE39-6380C2726841Q35810475-A5E52348-6F54-4926-8BFD-6F733D4E3EB5Q35824123-3257F87F-9E9C-4366-94A9-E16BB7F41173Q36182741-B487BF29-CCB3-418C-9BC6-BA1CCD49B039Q36233843-A75599B8-4E3B-40F0-B1D4-77B9FC18B000Q36337918-5FA6C1CE-A708-4DE7-B7FC-55D0823D78CEQ36471689-1E475292-4192-42E3-843F-1052E4A85C2DQ36512538-A750AA6A-0A5B-4B11-AD3A-EF7A23446674Q37379320-BCE88C21-EE6F-424C-8790-261A1687B893Q37382265-8D4C5D95-F4F7-4D6A-9757-FAB9F5F2C983Q37542270-4569F1F4-21D8-4CDC-A507-C508FA1C96C9Q38003387-08F7B72E-FA73-4450-B82F-79418EE1E055Q38357132-F761E612-6901-4E11-9214-3922A1964188Q39139762-8B8E47D7-50A2-42B1-8CB7-12D917478460Q40626944-B2AF5100-522B-4B7B-A754-9DEAF5D91F00Q42120906-C9E915A9-27A7-437B-8EF1-6163C2673D3BQ43135301-A78BED1F-626C-439E-9F0C-2E5AD78F3013Q44431114-127189A2-BBAC-466C-968D-150AE8AB72C7Q45117346-3281DDDD-0C66-4DA0-A253-903FEAC74E65Q46384943-E15C2C1F-0F3F-4FCD-9269-65395A37B7E2Q47756210-EB65BFD8-9EB3-4C78-83D8-533FDE324A70Q53350377-7E8C68A1-8602-4AE0-9024-D4FBC982990AQ54567153-F1C93058-48F1-4D6F-9B0E-B735DC8391BF
P2860
Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Rabaptin-5 is a novel fusion p ...... ronic myelomonocytic leukemia.
@en
type
label
Rabaptin-5 is a novel fusion p ...... ronic myelomonocytic leukemia.
@en
prefLabel
Rabaptin-5 is a novel fusion p ...... ronic myelomonocytic leukemia.
@en
P2093
P356
P1433
P1476
Rabaptin-5 is a novel fusion p ...... hronic myelomonocytic leukemia
@en
P2093
A J Barrett
D C Arthur
L A Krueger
M K Magnusson
P304
P356
10.1182/BLOOD.V98.8.2518
P407
P577
2001-10-01T00:00:00Z